Clot, Clot, Who's There?

In urgent, high-stakes situations—like major bleeding or emergency surgery—how should clinicians assess coagulation in patients on factor Xa inhibitors? And more importantly, are we focusing on the right signal? Join global experts as they explore: Why traditional assays (PT/aPTT, anti-Xa) often fall short in critical decision-making The role of functional testing in assessing true hemostatic potential How VMX-C001, a novel bypassing agent, challenges conventional approaches to reversal and monitoring Be sure to read the VMX-C001 study discussed in the episode: https://www.rpthjournal.org/article/S2475-0379(26)00033-6/fulltext?dgcid=raven_jbs_etoc_email Tune in now and subscribe to Clot, Clot, Who's There? for more expert conversations bridging science, practice, and global perspectives in thrombosis, hemostasis, and vascular medicine. Chapters 00:00 Introduction & Clinical Challenge 02:54 Assessing Factor Xa Inhibitors in Urgent/Emergent Situations 05:29 Why Standard Assays Fall Short 09:38 Functional Testing: dPT & dRVVT 12:35 VMX-C001 & Future Directions This episode was made possible through generous support from VarmX.

When it comes to antithrombotic therapy in coronary artery disease, the central question is no longer "What should everyone get?" It's "What's right for this patient?" In this episode, Drs. Heather Johnson, Ty Gluckman, and Davide Cappodano explore the modern balance between managing clotting and bleeding risk in patients on antiplatelets and anticoagulants. From the evolving role of aspirin and P2Y12 monotherapy to dual pathway inhibition and the management of CAD with atrial fibrillation, the conversation highlights a clear shift: less one-size-fits-all medicine, more individualized—and shared—decision-making. Tune in now and subscribe to Clot, Clot, Who's There? for more expert conversations bridging science, practice, and global perspectives in thrombosis, hemostasis, and vascular medicine. 00:00 – Welcome & Introduction 03:57 – Is Aspirin Still King? 10:26 – Shorter DAPT, Earlier Monotherapy 14:09 – When More Is More: the COMPASS regimen 17:49 – When Less Is More: CAD + AF

In this episode of Clot Clot Who's There, Aviva Schwartz, Director of Education at Vasculearn Network, speaks with Professor Gregory Lip about key anticoagulation and atrial fibrillation data from 2025 and what lies ahead in 2026. The discussion spans post–AF ablation management, holistic AF care, and emerging factor XI inhibitors shaping the future of thrombosis management. Tune in now and subscribe to Clot, Clot, Who's There? for more expert conversations bridging science, practice, and global perspectives in thrombosis, hemostasis, and vascular medicine. Chapters: 00:00 Welcome and Introduction 01:59 2025 Trial Highlights: Anticoagulation in Stable CAD and AF Ablation 07:27 High-Risk AF and Holistic Care 10:10 What's Coming in 2026: Factor XI Inhibitors and Upcoming Trials 11:51 Guidelines vs. Real-World Practice

Host Tara Lech is joined by Drs. Scott Woller and Virginia Silvari for a thoughtful conversation on anticoagulation stewardship: what it is, why it matters, and how it can help patients who need antithrombotic therapy. They share examples from their own practice, talk through common challenges, and offer simple steps for improving care across settings. Topics: What makes anticoagulation stewardship different from traditional management How to choose the right anticoagulant for each patient Practical system-level steps to support safe prescribing Lessons from U.S. and European practices Tips for reassessing therapy and managing periprocedural care Tune in now and subscribe to Clot, Clot, Who's There? for more expert conversations bridging science, practice, and global perspectives in thrombosis, hemostasis, and vascular medicine. 00:00 Welcome & Setting the Stage 02:01 What "Antithrombotic Stewardship" Really Means 05:49 Choosing the Right Agent for the Right Patient 13:39 Reassessment, Follow-Up, & Real-World Impact 22:50 Perioperative Management & Building a Stewardship Culture

Join JoMarie Monzon, NP (Cedars-Sinai, Vasculearn Network) as she welcomes moderator Dr. Cassra Arbabi and guests Drs. Donald Baril (Cedars-Sinai) and Efthymios (Makis) Avgerinos (Athens Medical Center) for a high-stakes discussion on acute limb ischemia (ALI). Explore U.S. and European approaches to this vascular emergency—from recognition to revascularization—and gain practical, globally informed insights on saving limbs and lives. Topics covered: Recognizing the "six Ps" of ALI Why urgency is critical Imaging pathways in the U.S. and Europe Open vs. endovascular strategies, including thrombolysis Anticoagulation and supportive therapy Future directions in ALI management Tune in now and subscribe to Clot, Clot, Who's There? for more expert conversations bridging science, practice, and global perspectives in thrombosis, hemostasis, and vascular medicine. 00:00 Introduction & Patient Case 05:05 Defining ALI and Why Time Is Limb 09:21 ALI Diagnosis & Early Management 13:47 Treatment Pathways 26:30 Beyond the OR 30:56 Key Takeaways

Join Dr. Jose Joglar, Chair of the 2023 U.S. AFib Guidelines, and Professor Gregory Lip, Chair of the ESC Council on Stroke, as they dive into the latest U.S. and European atrial fibrillation guidelines. From risk scores to rhythm control, they explore common ground, key differences, and the global shift toward holistic, patient-centered care. (Hint: coffee lovers with AFib, rejoice!) Whether you're a clinician navigating daily treatment decisions or a curious learner keeping up with cardiology guidelines, this is a must-listen conversation that reveals how far we've come in managing AFib and where we're headed next. Topics covered: Point-of-care pathways Anticoagulation and evolving risk scores Early rhythm control strategies Addressing AFib as a cardiometabolic disease Long-term impacts and future research priorities Tune in now and subscribe to stay updated in expert insights in thrombosis and cardiovascular medicine! For more resources, check out: ESC Guidelines: Clinician Perspective: https://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-2434-9244 2024 ESC Guidelines: https://academic.oup.com/eurheartj/article/45/36/3314/7738779?login=false 2023 U.S. Guidelines: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001193 00:00 Introduction 01:57 Philosophies Behind AFib Guidelines 08:11 Lifestyle and Prevention in AFib 08:58 Evidence for Holistic Care: mAFA & MIRACLE Trials 12:34 Stroke Risk Scores and Future Research Needs 17:29 Rhythm vs Rate Control: Evolving Practice 20:56 Ablation, Drug Therapy, and Shared Decision-Making 22:12 The Caffeine Myth 24:31 Key Takeaways

Does sex influence the risk of atrial fibrillation (AF)-related strokes? Is female sex truly an independent risk factor? And what common myths still cloud clinical understanding? In this episode, host Dr. Giulio Francesco Romiti (internal medicine specialist from Sapienza University of Rome, Italy) is joined by guests Dr. Geoff Barnes (cardiologist and vascular medicine specialist, University of Michigan, USA) and Dr. Bernadette Corica (internal medicine specialist and cardiologist in training in Modena, Italy, and honorary research fellow at the Liverpool Centre for Cardiovascular Science, UK) to explore the complex relationship between sex and stroke risk in patients with AF. Together, they unpack the latest research, challenge myths and misconceptions, and provide key insights on: ✅ Sex disparities in AF prevalence and stroke incidence✅ Why women with AF may experience worse outcomes✅ The role of anticoagulation therapy in men vs. women✅ Practical clinical strategies for stroke prevention Whether you're a clinician, researcher, or healthcare professional, this episode offers essential takeaways for optimizing patient care. 🎧 Tune in now and subscribe to stay updated on expert insights in thrombosis and cardiovascular medicine!